Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lipocine (NASDAQ:LPCN), a biopharmaceutical company focused on oral drug delivery, announced that management will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Company Showcase on bWednesday, May 20, 2026 at 3:00 PM ET
Investors can register online and view the fireside chat.
Details
News Market Reaction – LPCN
On May 18, the day this news came out, LPCN closed 2.21% below the previous close.
Data tracked by StockTitan Argus for the May 18 session.
Key Figures
- Fireside chat time
- 3:00 PM ET
- Scheduled time for A.G.P. Annual Healthcare Company Showcase appearance
- Fireside chat date
- May 20, 2026
- Date of Lipocine’s presentation at A.G.P. virtual showcase
Historical Context
-
Q1 results and confirmation that LPCN 1154 Phase 3 primary endpoint was not met.
-
Topline Phase 3 PPD data for LPCN 1154 showing primary endpoint not met in full set.
-
2025 results, cash of $14.9M, ATM use raising cash, and pipeline progress update.
-
Completion of Last Patient Last Visit in LPCN 1154 pivotal Phase 3 with favorable safety.
-
Completion of enrollment and dosing of 90 patients in Phase 3 LPCN 1154 PPD trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside Chat Details:
Time: 3:00 PM ET
Date: Wednesday, May 20, 2026
Investors can register for the conference and view the fireside chat here.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-agps-annual-virtual-healthcare-company-showcase-302773335.html
SOURCE Lipocine Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.